Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lungscape Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Lungscape Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters ORIGINAL ARTICLE Lungscape: Resected Non–Small-Cell Lung Cancer  Outcome by Clinical and Pathological Parameters Solange Peters, MD, PhD,* Walter Weder, MD,† Urania Dafni, ScD,‡ Keith M. Kerr, PhD,§ Lukas Bubendorf, MD,║ Peter Meldgaard, MD,¶ Kenneth J. O’Byrne, MD,# Anna Wrona, MD,** Johan Vansteenkiste, PhD,†† Enriqueta Felip, MD,‡‡ Antonio Marchetti, MD,§§ Spasenija Savic, MD,║ Shun Lu, PhD,║║ Egbert Smit, MD, PhD,¶¶ Anne-Marie Dingemans, PhD, ## Fiona H. Blackhall, PhD,*** Paul Baas, MD, PhD,††† Carlos Camps, MD,‡‡‡ Rafael Rosell, MD,§§§ Rolf A. Stahel, MD,║║║ on behalf of the ETOP Lungscape Investigators¶¶¶ 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA Introduction: The Lungscape project was designed to address the and IIIB, respectively (p < 0.001). Median and 5-year relapse-free impact of clinical, pathological, and molecular characteristics on out- survival (RFS) were 52.8 months and 47.3%, respectively. Distant come in resected non–small- cell lung cancer (NSCLC). relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% Materials and Methods: A decentralized biobank with fully anno- of patients. Based on multivariate analysis for the OS, RFS, and time tated tissue samples was established. Selection criteria for participat- to relapse, the factors significantly associated with all of them are ing centers included sufficient number of cases, tissue microarray http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Lungscape Resected Non&ndash;Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

Journal of Thoracic Oncology , Volume 9 (11) – Nov 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/lungscape-resected-non-ndash-small-cell-lung-cancer-outcome-by-FcHNK03bPN

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000320
pmid
25436801
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Lungscape: Resected Non–Small-Cell Lung Cancer  Outcome by Clinical and Pathological Parameters Solange Peters, MD, PhD,* Walter Weder, MD,† Urania Dafni, ScD,‡ Keith M. Kerr, PhD,§ Lukas Bubendorf, MD,║ Peter Meldgaard, MD,¶ Kenneth J. O’Byrne, MD,# Anna Wrona, MD,** Johan Vansteenkiste, PhD,†† Enriqueta Felip, MD,‡‡ Antonio Marchetti, MD,§§ Spasenija Savic, MD,║ Shun Lu, PhD,║║ Egbert Smit, MD, PhD,¶¶ Anne-Marie Dingemans, PhD, ## Fiona H. Blackhall, PhD,*** Paul Baas, MD, PhD,††† Carlos Camps, MD,‡‡‡ Rafael Rosell, MD,§§§ Rolf A. Stahel, MD,║║║ on behalf of the ETOP Lungscape Investigators¶¶¶ 47.7% for stages IIA and IIB, and 29.0% and 13.0% for stages IIIA Introduction: The Lungscape project was designed to address the and IIIB, respectively (p < 0.001). Median and 5-year relapse-free impact of clinical, pathological, and molecular characteristics on out- survival (RFS) were 52.8 months and 47.3%, respectively. Distant come in resected non–small- cell lung cancer (NSCLC). relapse was recorded for 44.4%, local for 26.0%, and both for 16.9% Materials and Methods: A decentralized biobank with fully anno- of patients. Based on multivariate analysis for the OS, RFS, and time tated tissue samples was established. Selection criteria for participat- to relapse, the factors significantly associated with all of them are ing centers included sufficient number of cases, tissue microarray

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Nov 1, 2014

References